Suppr超能文献

利用与噻唑相连的新型吡唑并[3,4-d]嘧啶支架作为潜在的EGFR/HER2双激酶抑制剂来克服拉帕替尼耐药性乳腺癌:设计、合成、计算机模拟对接和分子动力学模拟

Exploitation of novel pyrazolo[3,4-d]pyrimidine scaffold tethered to thiazole as potential EGFR/HER2 dual kinase inhibitor to overcome lapatinib resistant breast cancer: Design, synthesis, in silico docking and molecular dynamic simulation.

作者信息

Salem Ibrahim M, El-Sabbagh Osama I, Mostafa Samia M, Salama Ismail, Al-Awadh Mohammed A, Alkhilaiwi Faris A, Yonbawi Ahmed R, Binothman Najat, Hayallah Alaa M, Ibrahim Tarek S

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sphinx University, New Assiut City, Assiut 71515, Egypt; Pharmaceutical Chemistry Department, College of Pharmacy, Al-Farahidi University, Baghdad 10070, Iraq.

Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.

出版信息

Bioorg Chem. 2025 Aug;163:108671. doi: 10.1016/j.bioorg.2025.108671. Epub 2025 Jun 3.

Abstract

The overexpression of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) is widely acknowledged as having diagnostic and prognostic significance in breast cancer, and despite lapatinib (EGFR/HER2 dual inhibitor) achieves high cure rates in most breast cancer cases, many patients develop resistance and don't respond to it. Thus, the design of new approaches of EGFR/HER2 inhibitors for the management of breast cancer is an urgent need. Herein, novel pyrazolo [3,4-d]pyrimidine derivatives tethered to hydrazones, thiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles were developed and evaluated as EGFR/HER2 dual inhibitors. The thiazole bearing compound 10f achieved the highest EGFR/HER2 dual inhibitory potential with IC values of 0.09 and 0.08 μM respectively, along with better cytotoxic IC levels against different cancer cell lines such as HePG-2 (3.90 μM), HCT-116 (7.35 μM) and MCF-7 (2.84 μM). Compound 10f likewise achieved substantial elevated cytotoxic activities against lapatinib-resistant breast cancer cell lines SKBr3, BT474 and MDA-MB-453. The Flow Cytometry for the compound 10f was accomplished against MCF-7 breast cancer cell line, and the results demonstrated the capability of it to induce apoptosis and arrest the MCF-7 cell cycle in the G0/G1 phase. The in-silico docking investigations exposed that, the pyrazolo [3,4-d]pyrimidine bearing thiazole 10f demoed high affinity for the ATP-binding domains of both EGFR and HER2 with considerable binding scoring of -4.768 and - 8.572 Kcal/mol respectively, comparable with the lapatinib reference (-5.599 and - 7.442 Kcal/mol). Finally, the stabilities of the formed complexes of compound 10f with both EGFR and HER2 targets, were considered by a distinctive atomistic 200 ns dynamic simulation approach. The MD simulation trajectories were operated and approved the stability of the formed complexes under the dynamic solvated conditions.

摘要

表皮生长因子受体(EGFR)和人表皮生长因子受体2(HER2)的过表达在乳腺癌中具有诊断和预后意义,这一点已得到广泛认可。尽管拉帕替尼(EGFR/HER2双重抑制剂)在大多数乳腺癌病例中能实现高治愈率,但许多患者会产生耐药性且对其无反应。因此,迫切需要设计新的EGFR/HER2抑制剂方法来治疗乳腺癌。在此,我们开发了与腙、噻唑、1,3,4-噻二唑和1,2,4-三唑相连的新型吡唑并[3,4-d]嘧啶衍生物,并将其作为EGFR/HER2双重抑制剂进行评估。含噻唑的化合物10f具有最高的EGFR/HER2双重抑制潜力,其IC值分别为0.09和0.08 μM,对不同癌细胞系如HePG-2(3.90 μM)、HCT-116(7.35 μM)和MCF-7(2.84 μM)具有更好的细胞毒性IC水平。化合物10f对拉帕替尼耐药的乳腺癌细胞系SKBr3、BT474和MDA-MB-453同样具有显著提高的细胞毒性活性。对化合物10f针对MCF-7乳腺癌细胞系进行了流式细胞术检测,结果表明其能够诱导细胞凋亡并使MCF-7细胞周期停滞在G0/G1期。计算机模拟对接研究表明,含噻唑的吡唑并[3,4-d]嘧啶10f对EGFR和HER2的ATP结合域具有高亲和力,结合评分分别为-4.768和-8.572千卡/摩尔,与拉帕替尼对照物(-5.599和-7.442千卡/摩尔)相当。最后,通过独特的原子尺度200纳秒动态模拟方法研究了化合物10f与EGFR和HER2靶点形成的复合物的稳定性。进行了分子动力学模拟轨迹研究,并证实了在动态溶剂化条件下形成的复合物的稳定性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验